Clinical Trials Sponsored by GW Pharmaceuticals Ltd.

Total 4415 results

Clarity Pharmaceuticals Ltd

Completed

Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA (PROPELLER) (PROPELLER)

Prostatic Neoplasms

Australia
Orasis Pharmaceuticals Ltd.

Completed

An Evaluation of the Safety of CSF-1 in Presbyopic Subjects

Presbyopia

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate ACT-132577 in Healthy Male Subjects

Healthy Subjects

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

Clinical Study to Assess Body Fluid Homeostasis After Administration of ACT-132577 in Healthy Subjects

Healthy Subjects

Switzerland
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Effect of ACT-132577 on the Pharmacokinetics of Midazolam and 1-hydroxy Midazolam in Healthy Male Subjects

Healthy Subjects

United States
Idorsia Pharmaceuticals Ltd.

Completed

The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics

Healthy Subjects | Hepatic Impairment

Germany, Poland
Idorsia Pharmaceuticals Ltd.

Completed

Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension

Essential Hypertension

United States, Canada, Israel, Puerto Rico
Idorsia Pharmaceuticals Ltd.

Completed

A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease

Stable Coronary Artery Disease

Denmark, Netherlands, Singapore, Canada, United Kingdom, United States, Germany, Sweden
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects

Healthy

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy Subjects

Healthy Subject

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

A Comparative Study of Selatogrel (ACT-246475) Formulations in Healthy Subjects

Healthy Subjects

United States
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Examine the Effect of Daridorexant on the Way the Body Absorbs, Distributes, and Gets Rid of Dabigatran and Rosuvastatin in Healthy Male Subjects

Healthy

Czechia
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-777991 in Healthy Subjects

Healthy

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Effect of Single and Repeated Oral Doses of ACT-539313 on What the Body Does to Flurbiprofen, Omeprazole, Midazolam in Healthy Subjects

Healthy

Germany
Overseas Pharmaceuticals, Ltd.

Completed

To Evaluate the Food Effect and the Absorption Profile of Ibuprofen Modified-Release Tablets 800 mg

Chronic Pain

China
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate the Effect of ACT-774312 in Subjects With Bilateral Nasal Polyposis

Bilateral Nasal Polyposis

Germany, Belgium
Fochon Pharmaceuticals, Ltd.

Completed

Study of FCN-437c in Patients With Advanced Solid Tumors (FCN-437c)

Solid Tumor, Adult

United States
Idorsia Pharmaceuticals Ltd.

Completed

Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep

Insomnia Disorder

United States, Germany, Canada, Denmark, Poland, Spain, Switzerland, Belgium, Bulgaria, Finland, France, Hungary, Korea, Republic of, Sweden
KalVista Pharmaceuticals, Ltd.

Completed

A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers

Hereditary Angioedema

United Kingdom
Kiniksa Pharmaceuticals, Ltd.

Completed

A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

Plaque Psoriasis | Chronic Idiopathic Urticaria | Lichen Planus | Lichen Simplex Chronicus | Chronic Idiopathic Pruritus

United States
Alembic Pharmaceuticals Ltd.

Completed

Oral Bio-equivalence Study

Bioequivalence | Safety

Canada
Idorsia Pharmaceuticals Ltd.

Completed

Natural History Study for Pediatric Patients With Early Onset of Either GM1 Gangliosidosis, GM2 Gangliosidoses, or Gaucher Disease Type 2 (RETRIEVE)

GM2 Gangliosidosis | GM1 Gangliosidosis | Tay-Sachs Disease | Sandhoff Disease | Gaucher Disease, Type 2 | AB Variant Gangliosidosis GM2

United States, Spain, Germany, Italy, Belgium, Brazil, France, Portugal, Switzerland, United Kingdom
BiondVax Pharmaceuticals ltd.

Completed

A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine

Influenza

Poland
AFT Pharmaceuticals, Ltd.

Completed

Maxigesic IV Phase 3 Bunionectomy Study

Post Operative Pain

United States
Kiniksa Pharmaceuticals, Ltd.

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects

Healthy Volunteers

Australia, United States
KalVista Pharmaceuticals, Ltd.

Completed

Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)

Diabetic Macular Edema

United States
Faron Pharmaceuticals Ltd

Terminated

Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA (INFORAAA)

Preventive Medicine | Multi Organ Failure

Lithuania, Estonia, Finland
Idorsia Pharmaceuticals Ltd.

Completed

A Study in Healthy Male Subjects to Investigate the Effect of Famotidine and Efavirenz on the Way the Body Takes up, Distributes, and Gets Rid of Daridorexant.

Healthy

Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment

Hepatic Impairment

Switzerland
Neurim Pharmaceuticals Ltd.

Completed

Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)

Alzheimer's Disease

United States
Idorsia Pharmaceuticals Ltd.

Completed

Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping (CONSCIOUS-2)

Aneurysmal Subarachnoid Hemorrhage

United States, Spain, Denmark, Hong Kong, India, Norway, Canada, Switzerland, China, France, Australia, Serbia, Latvia, Sweden, Austria, Germany, Slovenia, Belgium, Croatia, Czechia, Finland, Italy, Korea, Republic of, New Zealand, Poland, Russian Federation and more
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate ID-085 in People With Mild, Moderate, and Severe Kidney Disease

Renal Impairment

Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Study in Healthy Subjects to Investigate Whether Administration of Lucerastat Can Affect Normal Heart Function

Healthy

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users

Healthy Recreational Drug Users

United States, Canada
Idorsia Pharmaceuticals Ltd.

Completed

Effect of ACT-451840 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Subjects

Healthy Subjects

Australia
Britannia Pharmaceuticals Ltd.

Completed

Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.

Parkinson's Disease
Britannia Pharmaceuticals Ltd.

Completed

Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease (TOLEDO)

Parkinson's Disease

Spain, United Kingdom, Netherlands, Austria, Denmark, France, Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Clinical Study to Investigate the Food Effect on the Pharmacokinetics of ACT-541468 in Healthy Male Subjects

Healthy

Czechia
Idorsia Pharmaceuticals Ltd.

Completed

A Study in Healthy Subjects to Investigate Whether Administration of Clazosentan Can Affect Normal Heart Function

Healthy Subjects

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis (SAR)

Seasonal Allergic Rhinitis

United States
Idorsia Pharmaceuticals Ltd.

Completed

Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH) (CONSCIOUS-1)

Aneurysmal Subarachnoid Hemorrhage

United States, Canada
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate Cenerimod in Healthy Male Subjects

Healthy Subjects

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

Tezosentan in the Treatment of Acute Heart Failure (VERITAS 2)

Acute Heart Failure | Acute Decompensation of Chronic Heart Failure | New Onset of Heart Failure

United States, Hungary, Australia, Czechia, Germany, Italy, Norway, United Kingdom
Idorsia Pharmaceuticals Ltd.

Terminated

A Study to Evaluate if AC-084 is Safe, Its Fate in the Body as Well as Its Potential Effects on the Body in Healthy Subjects

Healthy Subjects

United Kingdom
Idorsia Pharmaceuticals Ltd.

Completed

Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949

Healthy Subjects

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

Evaluation of the Efficacy and Safety of Clazosentan in Reversing Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage (REVERSE)

Aneurysmal Subarachnoid Hemorrhage

Finland, France, Switzerland
Idorsia Pharmaceuticals Ltd.

Terminated

Tezosentan in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, France, Switzerland
Idorsia Pharmaceuticals Ltd.

Terminated

Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery

Heart Diseases | Hypertension, Pulmonary

United States, United Kingdom, France, Israel, Canada, Sweden, Austria, Serbia, India, Czechia, Germany, Italy, Poland, Slovakia
Neurim Pharmaceuticals Ltd.

Completed

Sleep Laboratory Study to Investigate the Safety and Efficacy of Neu-P11 in Primary Insomnia Patients

Primary Insomnia

United States
Neurim Pharmaceuticals Ltd.

Completed

Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor

Sleep Disorder | Alzheimer's Disease

United States, United Kingdom, Israel

3

Subscribe